Regeneron and Sanofi Launch New Study on Dupilumab for Children’s Growth and Bone Health

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to <12 Years of Age With Severe Atopic Dermatitis Treated With Dupilumab.' The study aims to evaluate whether dupilumab, an approved treatment for atopic dermatitis, can improve growth and bone strength in children with severe cases that are not well-managed by topical treatments. Additionally, the study will monitor potential side effects of dupilumab.

The intervention being tested is dupilumab, a drug already approved for treating moderate-to-severe atopic dermatitis in both adults and children. The study will explore its effects specifically on growth and bone mineral density in children with severe atopic dermatitis.

This is an interventional study with a single-group assignment, meaning all participants will receive the same treatment without a control group. The study is open-label, so both researchers and participants will know what treatment is being administered. The primary purpose of the study is treatment-focused.

The study is not yet recruiting as of its last update on September 15, 2025. Key dates include the study’s initial submission on September 15, 2025, with no results submitted yet. The timeline for primary and estimated completion is not specified.

The study’s outcomes could influence Regeneron and Sanofi’s stock performance, particularly if dupilumab demonstrates significant benefits in this new age group. Positive results may enhance investor sentiment and position the companies favorably against competitors in the dermatology market.

The study is ongoing, with further details available on the ClinicalTrials portal.